EU/3/05/340: Orphan designation for the treatment of myelodysplastic / myeloproliferative diseases

imatinib mesilate

Table of contents

Overview

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in April 2012 on request of the sponsor.

On 23 December 2005, orphan designation (EU/3/05/340) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for imatinib mesilate for the treatment of myelodysplastic / myeloproliferative diseases

Imatinib mesilate for treatment of myelodysplastic / myeloproliferative diseases has been authorised in the EU as Glivec since 28 November 2006.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
imatinib mesilate
Medicine name
Glivec
Intented use
Treatment of myelodysplastic / myeloproliferative diseases
Orphan designation status
Expired
EU designation number
EU/3/05/340
Date of designation
23/12/2005
Sponsor
Novartis Europharm Limited
Frimley Business Park
Camberley GU16 7SR
United Kingdom
Tel. +41 613 2411 11
E-mail: orphan.enquiries@novartis.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating